DelveInsight’s, “Ulcerative Colitis Pipeline Insight, 2022,” report provides comprehensive insights about 110+ companies and 110+ pipeline drugs in Ulcerative Colitis pipeline landscape. It covers the Ulcerative Colitis pipeline drug profiles, including Ulcerative Colitis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Ulcerative Colitis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Ulcerative Colitis NDA approvals (if any), and product development activities comprising the technology, Ulcerative Colitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from Ulcerative Colitis Pipeline Insight Report
- DelveInsight’s Ulcerative Colitis Pipeline report depicts a robust space with 110+ active players working to develop 110+ pipeline therapies for Ulcerative Colitis.
- The leading Ulcerative Colitis Companies such as Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer Ingelheim, Janssen Research & Development, Lycera, LG Chem, Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay Pharmaceutical, GlaxoSmithKline, Galapagos, Celgene, Gossamer Bio, Eisai, UCB, Suzhou Connect Biopharmaceuticals, Landos Biopharma, Seres Therapeutics, Abivax, Genentech, ParaTech A/S, I-Mab Biopharma, Sublimity Therapeutics Holdco, Reistone Biopharma, Qu Biologics, PurGenesis Technologies, Protagonist Therapeutics, Pfizer, Palobiofarma, Novartis Pharmaceuticals, Bristol-Myers Squibb, Bridge Biotherapeutics, Amgen, Allergan, Applied Molecular Transport, AbGenomics International, Protalix BioTherapeutics, LTT Bio-Pharma Co Ltd, Dongwha pharma, Seres Therapeutics, Innovation Pharmaceuticals, Holy Stone Healthcare, SLA Pharma, OSE Immunotherapeutics, Bridge Biotherapeutics, Mitsubishi Tanabe Pharma, Sterna Biologicals, Mesoblast, Oncostellae, First Wave Bio, Oppilan Pharma, NeuClone, Morphic Therapeutic, Metacrine, LG Chem, Koutif Therapeutics, Kiniksa Pharmaceuticals, Avaxia Biologics, Algernon Pharmaceuticals, Akeso Biopharma, Kaleido Biosciences, Rebiotix, and many more.
- Promising Ulcerative Colitis therapies such as ABX464, adalimumab, endoscopy, Budesonide MMX® 6 mg, tralokinumab, BBT-401-1S, Filgotinib, PTM filgotinib, Mesalazine, and others
- The Ulcerative Colitis companies and academics are working to assess challenges and seek opportunities that could influence Ulcerative Colitis R&D. The Ulcerative Colitis pipeline therapies under development are focused on novel approaches to treat/improve Ulcerative Colitis.
To explore more information on the latest breakthroughs in the Ulcerative Colitis Pipeline treatment landscape of the report, click here @ Ulcerative Colitis Pipeline Outlook
Ulcerative Colitis Overview
Ulcerative colitis is a chronic disease of the large intestine, in which the lining of the colon become inflamed and develops tiny open sores or ulcers. Those ulcers produce pus and mucous, which causes abdominal pain. It usually begins in the rectum and spreads upwards. The inflammation causes bowel to move its content rapidly and empty frequently. Ulcerative colitis begins gradually and become worse over the period of time. Ulcerative colitis also known as inflammatory bowel disease. Ulcerative colitis symptoms range from mild to severe and varies among affected people. The predominant symptoms in ulcerative colitis is diarrhea, which can be associated with the discharge of blood in the stool.
Recent Developmental of Ulcerative Colitis Treatment Landscape
- Mirikizumab is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of interleukin 23. Mirikizumab is being studied for the treatment of immune-mediated diseases, including ulcerative colitis and Crohn’s disease.
- Risankizumab is an antagonistic anti-CD40 antibody. The CD40-CD40L pathway may play a major role in immune disease such as lupus nephritis, Crohn’s disease and ulcerative colitis.
- Etrasimod is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5. It is being investigated for a range of immuno-inflammatory diseases, including ulcerative colitis, Crohn’s disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata.
Request a sample and discover the recent advances in Ulcerative Colitis Ongoing Clinical Trial Analysis and Medications, click here @ Ulcerative Colitis Treatment Landscape
Ulcerative Colitis Emerging Drugs Profile
Mirikizumab: Eli Lilly and Company
Mirikizumab is a humanized IgG4 monoclonal antibody that binds to the p19 subunit of interleukin 23. Mirikizumab is being studied for the treatment of immune-mediated diseases, including ulcerative colitis and Crohn’s disease.
Risankizumab: AbbVie
Risankizumab is an antagonistic anti-CD40 antibody. The CD40-CD40L pathway may play a major role in immune disease such as lupus nephritis, Crohn’s disease and ulcerative colitis.
Etrasimod: Pfizer
Etrasimod is an oral, once-a-day, selective sphingosine 1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5. It is being investigated for a range of immuno-inflammatory diseases, including ulcerative colitis, Crohn’s disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata
DelveInsight’s Ulcerative Colitis Pipeline Report covers around 110+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Scope of the Ulcerative Colitis Pipeline Report
- Coverage- Global
- Ulcerative Colitis Companies- Eli Lilly and Company, Lipid Therapeutics, Hoffmann-La Roche, Arena Pharmaceuticals, InDex Pharmaceuticals, EA Pharma, Theravance Biopharma, Boehringer Ingelheim, Janssen Research & Development, Lycera, LG Chem, Iltoo Pharma, Immunic, Hutchison Medipharma, Tianjin Hemay Pharmaceutical, GlaxoSmithKline, Galapagos, Celgene, Gossamer Bio, Eisai, UCB, Suzhou Connect Biopharmaceuticals, Landos Biopharma, Seres Therapeutics, Abivax, Genentech, ParaTech A/S, I-Mab Biopharma, Sublimity Therapeutics Holdco, Reistone Biopharma, Qu Biologics, PurGenesis Technologies, Protagonist Therapeutics, Pfizer, Palobiofarma, Novartis Pharmaceuticals, Bristol-Myers Squibb, Bridge Biotherapeutics, Amgen, Allergan, Applied Molecular Transport, AbGenomics International, Protalix BioTherapeutics, LTT Bio-Pharma Co Ltd, Dongwha pharma, Seres Therapeutics, Innovation Pharmaceuticals, Holy Stone Healthcare, SLA Pharma, OSE Immunotherapeutics, Bridge Biotherapeutics, Mitsubishi Tanabe Pharma, Sterna Biologicals, Mesoblast, Oncostellae, First Wave Bio, Oppilan Pharma, NeuClone, Morphic Therapeutic, Metacrine, LG Chem, Koutif Therapeutics, Kiniksa Pharmaceuticals, Avaxia Biologics, Algernon Pharmaceuticals, Akeso Biopharma, Kaleido Biosciences, Rebiotix, and others.
- Ulcerative Colitis Therapies- ABX464, adalimumab, endoscopy, Budesonide MMX® 6 mg, tralokinumab, BBT-401-1S, Filgotinib, PTM filgotinib, Mesalazine, and others.
- Ulcerative Colitis Pipeline Therapeutics Assessment: Product Type, Molecule Type, Mechanism of Action, Route of Administration
Table of content
- Introduction
- Ulcerative Colitis Executive Summary
- Ulcerative Colitis: Overview
- Ulcerative Colitis Pipeline Therapeutics
- Ulcerative Colitis Pipeline Therapeutic Assessment
- Ulcerative Colitis– DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- Ulcerative Colitis Collaboration Deals
- Late Stage Products (Preregistration)
- Mirikizumab: Eli Lilly and Company
- Drug profiles in the detailed report…..
- Late Stage Products (Phase III)
- Upadacitinib: AbbVie
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II/III)
- TD-1473: Theravance Biopharma
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- LYC-30937: Lycera
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Remestemcel-L: Mesoblast
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- OPL-002: Oppilan Pharma
- Drug profiles in the detailed report…..
- IND Stage Products
- SVT-1A710: Servatus
- Drug profiles in the detailed report…..
- Preclinical Stage Products
- ATH-001: Athos Therapeutics
- Drug profiles in the detailed report…..
- Discovery Stage Products
- NM 001: NuMedii
- Inactive Products
- Ulcerative Colitis Key Companies
- Ulcerative Colitis Key Products
- Ulcerative Colitis- Unmet Needs
- Ulcerative Colitis- Market Drivers and Barriers
- Ulcerative Colitis- Future Perspectives and Conclusion
- Ulcerative Colitis Analyst Views
- Ulcerative Colitis Key Companies
- Appendix
Got Queries? Find out the related information on Ulcerative Colitis Mergers and acquisitions, Ulcerative Colitis Licensing Activities @ Ulcerative Colitis Emerging Drugs, and Recent Trends
Related Report– Interbody Cages Market | Acoustic Neuroma Market
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/report-store/meningioma-market